-
1
-
-
77950238310
-
Autoantibodies in rheumatoid arthritis: Rheumatoid factors and anticitrullinated protein antibodies
-
Song YW, Kang EH. Autoantibodies in rheumatoid arthritis: rheumatoid factors and anticitrullinated protein antibodies. QJM 2010;103:139-46.
-
(2010)
QJM
, vol.103
, pp. 139-146
-
-
Song, Y.W.1
Kang, E.H.2
-
2
-
-
7044279878
-
Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: Diagnostic value, associations with radiological progression rate, and extra-articular manifestations
-
De Rycke L, Peene I, Hoffman IE, et al. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis 2004;63:1587-93.
-
(2004)
Ann Rheum Dis
, vol.63
, pp. 1587-1593
-
-
De Rycke, L.1
Peene, I.2
Hoffman, I.E.3
-
3
-
-
33645116507
-
Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset
-
Berglin E, Johansson T, Sundin U, et al. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis 2006;65:453-8.
-
(2006)
Ann Rheum Dis
, vol.65
, pp. 453-458
-
-
Berglin, E.1
Johansson, T.2
Sundin, U.3
-
4
-
-
34447316727
-
Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis
-
Niewold TB, Harrison MJ, Paget SA. Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis. QJM 2007;100:193-201.
-
(2007)
QJM
, vol.100
, pp. 193-201
-
-
Niewold, T.B.1
Harrison, M.J.2
Paget, S.A.3
-
5
-
-
77956036473
-
2010 rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative
-
Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-8.
-
(2010)
Ann Rheum Dis
, vol.69
, pp. 1580-1588
-
-
Aletaha, D.1
Neogi, T.2
Silman, A.J.3
-
6
-
-
77953696525
-
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
-
Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
-
(2010)
Ann Rheum Dis
, vol.69
, pp. 964-975
-
-
Smolen, J.S.1
Landewé, R.2
Breedveld, F.C.3
-
7
-
-
34848842839
-
Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF-alpha treated patients
-
Bobbio-Pallavicini F, Caporali R, Alpini C, et al. Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF-alpha treated patients. Ann N Y Acad Sci 2007;1109:287-95.
-
(2007)
Ann N y Acad Sci
, vol.1109
, pp. 287-295
-
-
Bobbio-Pallavicini, F.1
Caporali, R.2
Alpini, C.3
-
8
-
-
34147220774
-
High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis
-
Bobbio-Pallavicini F, Caporali R, Alpini C, et al. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis 2007;66:302-7.
-
(2007)
Ann Rheum Dis
, vol.66
, pp. 302-307
-
-
Bobbio-Pallavicini, F.1
Caporali, R.2
Alpini, C.3
-
9
-
-
1942440157
-
Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement
-
Alessandri C, Bombardieri M, Papa N, et al. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 2004;63:1218-21.
-
(2004)
Ann Rheum Dis
, vol.63
, pp. 1218-1221
-
-
Alessandri, C.1
Bombardieri, M.2
Papa, N.3
-
10
-
-
77950307115
-
Treating rheumatoid arthritis to target: Recommendations of an international task force
-
Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
-
(2010)
Ann Rheum Dis
, vol.69
, pp. 631-637
-
-
Smolen, J.S.1
Aletaha, D.2
Bijlsma, J.W.3
-
11
-
-
36448970927
-
The use of databases for quality assessment in rheumatoid arthritis
-
Stamm TA, Aletaha D, Pflugbeil S, et al. The use of databases for quality assessment in rheumatoid arthritis. Clin Exp Rheumatol 2007;25:82-5.
-
(2007)
Clin Exp Rheumatol
, vol.25
, pp. 82-85
-
-
Stamm, T.A.1
Aletaha, D.2
Pflugbeil, S.3
-
12
-
-
0023945481
-
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
-
Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
-
(1988)
Arthritis Rheum
, vol.31
, pp. 315-324
-
-
Arnett, F.C.1
Edworthy, S.M.2
Bloch, D.A.3
-
13
-
-
0344127554
-
A simplified disease activity index for rheumatoid arthritis for use in clinical practice
-
Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003;42:244-57.
-
(2003)
Rheumatology (Oxford)
, vol.42
, pp. 244-257
-
-
Smolen, J.S.1
Breedveld, F.C.2
Schiff, M.H.3
-
14
-
-
84862560815
-
Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index
-
Aletaha D, Martinez-Avila J, Kvien TK, et al. Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index. Ann Rheum Dis 2012.
-
(2012)
Ann Rheum Dis
-
-
Aletaha, D.1
Martinez-Avila, J.2
Kvien, T.K.3
-
15
-
-
67349090358
-
Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: A one-year prospective study
-
Atzeni F, Sarzi-Puttini P, Dell' Acqua D, et al. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther 2006;8:R30.
-
(2006)
Arthritis Res Ther
, vol.8
-
-
Atzeni, F.1
Sarzi-Puttini, P.2
Dell'Acqua, D.3
-
16
-
-
29144519684
-
The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis
-
Chen HA, Lin KC, Chen CH, et al. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:35-9.
-
(2006)
Ann Rheum Dis
, vol.65
, pp. 35-39
-
-
Chen, H.A.1
Lin, K.C.2
Chen, C.H.3
-
17
-
-
13244261140
-
Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis
-
De Rycke L, Verhelst X, Kruithof E, et al. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Ann Rheum Dis 2005;64:299-302.
-
(2005)
Ann Rheum Dis
, vol.64
, pp. 299-302
-
-
De Rycke, L.1
Verhelst, X.2
Kruithof, E.3
-
19
-
-
84859449924
-
The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis
-
Hashizume M, Mihara M. The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis. Arthritis 2011;2011:765624.
-
(2011)
Arthritis
, vol.2011
, pp. 765624
-
-
Hashizume, M.1
Mihara, M.2
-
20
-
-
0036166461
-
Treating rheumatoid arthritis early: A window of opportunity?
-
O'Dell JR. Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum 2002;46:283-5.
-
(2002)
Arthritis Rheum
, vol.46
, pp. 283-285
-
-
O'Dell, J.R.1
-
21
-
-
10444250299
-
Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody
-
Mikuls TR, O'Dell JR, Stoner JA, et al. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum 2004;50:3776-82.
-
(2004)
Arthritis Rheum
, vol.50
, pp. 3776-3782
-
-
Mikuls, T.R.1
O'Dell, J.R.2
Stoner, J.A.3
-
22
-
-
79957647039
-
Predictors of radiographic progression in the ESPOIR cohort: The season of first symptoms may influence the short-term outcome in early arthritis
-
Mouterde G, Lukas C, Logeart I, et al. Predictors of radiographic progression in the ESPOIR cohort: the season of first symptoms may influence the short-term outcome in early arthritis. Ann Rheum Dis 2011;70:1251-6.
-
(2011)
Ann Rheum Dis
, vol.70
, pp. 1251-1256
-
-
Mouterde, G.1
Lukas, C.2
Logeart, I.3
|